Leadership Team

Aidan Synnott has 20 years of experience in biomedical research. He has led businesses in the USA and Europe since 2013 under the umbrella of Charles River Laboratories, where he spent 16 years. Over this period, he worked across the globe in operational and business development roles, notably managing operations across the Discovery and Safety Assessment and Research Models portfolio. He played a leading role in the integration of acquired companies on both continents during his tenure. Under his recent tenure as Corporate Vice-President, Global Discovery Services, the company passed the milestones of delivering 500 patents and 100 clinical candidates for its customers.

Aidan completed a Doctorate in Biotechnology at the Tokyo Institute of Technology under a scholarship from the Japanese government, and received the Kamata Gold Medal. He also has degrees from Trinity College, Dublin. Over the course of his career, he has co-authored a number of peer-reviewed papers and publications and is listed on several patents.

In March 2025, Aidan Synnott was appointed as Chief Executive Officer of Oncodesign Services.

Jessy Favari is a senior operations executive with more than 15 years of leadership experience driving transformation, operational excellence, and business performance across the life sciences, industrial, and services sectors. He currently serves as Group Chief Operating Officer and Site Director at Oncodesign Services, where he leads operational strategy, organizational development, and performance improvement initiatives supporting the company’s growth ambitions.

Prior to joining Oncodesign Services, Jessy held executive leadership roles at Pierre Fabre, overseeing large-scale R&D and administrative operations across multiple sites, and at Phytocontrol Group, where he contributed to business expansion, profitability improvement, and organizational transformation.

An engineer by training and a certified Lean Green Belt, he is recognized for combining strategic vision with hands-on execution. His expertise spans operational excellence, P&L management, organizational transformation, facility and laboratory operations, and leading multidisciplinary teams in highly regulated and innovation-driven environments.

Stéphanie Belattar has a degree in business law from the University of Strasbourg, supplemented by a course in international trade (ESCI). She held various positions as legal manager in pharmaceutical companies for around ten years, covering the French and international markets, in particular for the Europe, CIS, Maghreb and Middle East zones, with companies such as VWR, Laboratoires COOPER and INNOTECH International. At the same time, she worked as a consultant  in business law at the Conservatoire National des Arts et Métiers in Paris. Stéphanie went on to work as head of legal affairs and then group legal director and DPO in various areas of activity within medium-sized companies in the intralogistics, security and services sectors.

With almost 20 years’ experience in business law acquired with family-owned groups, foreign groups and private equity funds, Stéphanie joined Oncodesign Services in May 2023 and will be in charge of the legal department, including the role of Data Protection Officer (DPO) for all Oncodesign Services sites.

Sébastien brings more than 20 years of experience in Human Resources, including over a decade as HR Director, across distribution, technology and life sciences. A graduate of ISEG Lyon, he began his career at Randstad before holding HR management roles in organizations ranging from 100 to more than 1,000 employees.
He went on to serve as HR Director at Tech Data, supporting a 400-strong sales force, and then at Hewlett Packard Enterprise (later DXC Technology), where he managed an international scope of 2,500 people under a dual France/international reporting line. In both companies, he led post-acquisition integrations, including the harmonization of compensation and benefits policies.

He then moved into the pharmaceutical industry as HR Director France at Adare Pharmaceuticals, where he sat on the site leadership team of its manufacturing plant and designed an international leadership program in partnership with the Center for Leadership.

Sébastien joined Oncodesign Services in 2023 as Chief Human Resources Officer and member of the Executive Committee. He oversees HR, employment law and organizational matters, with a strong focus on aligning people, organization and governance with the company’s strategy and value creation. He has recognized expertise in French labor law, social dialogue, business transformation and executive compensation.

Dr. Marc Hillairet de Boisferon is a preclinical pharmacologist with more than 25 years of research experience in oncology and therapeutic development. At Oncodesign Services, he leads scientific and technical teams conducting preclinical studies to characterize anticancer activity, pharmacokinetics, and non-regulatory toxicity. His expertise includes patient-derived xenografts, syngeneic and humanized models, therapeutic combinations, and resistance to treatment.

Marc joined Oncodesign Services in 2003, progressing from Project Manager to Study Director and Head of Oncology Pharmacology. Previously, he held a role at Diatos, following doctoral research at INSERM investigating strategies to improve the selective delivery of therapeutic agents to tumor cells.

He holds a PhD in Molecular Pharmacochemistry from Université René Descartes, Paris V. His publication record includes (but is not limited to) first-author research on dual-antigen tumor targeting and the selectivity of radiolabeled peptides, alongside collaborative work on anticancer combination therapies. His contributions presented at AACR and EORTC conferences address immune checkpoint inhibition, antibody–drug conjugates, humanized mouse models, and endocrine-resistant breast cancer, reflecting substantial experience in the experimental evaluation of oncology therapeutics.

Eftychia brings over 25 years of international experience in nuclear medicine, radiopharmaceutical development, and translational oncology research. Prior to joining Oncodesign Services, she held key roles at ABX-CRO and Advanced Accelerator Applications (a Novartis company), contributing to the development of Radiotherapies such as Lutathera®. Dr. Koumarianou holds a Ph.D. from the University of Athens and has conducted postdoctoral research at institutions including Demokritos, Polatom, Duke University and Duke-NUS Medical School.